Minapharm Pharmaceuticals and Bayer AG have signed a strategic cooperation agreement to localize pharmaceutical manufacturing in women’s health and family planning, targeting both local and African markets.
The collaboration aligns with Egypt’s national priorities by promoting local pharmaceutical production, enhancing access to essential women’s health solutions, and directly supporting the National Population and Development Strategy. It also aims to expand Egypt’s pharmaceutical export capacity across Africa, reinforcing the country’s position as a regional hub for medicine manufacturing.
This milestone builds on Minapharm’s expertise in technology transfer and global partnerships, cementing its role as a pioneering industrial platform capable of addressing national health priorities while serving regional and African markets.
The agreement was signed during the Global Population Health Development Congress (GPHDC), in the presence of key government and health leaders. Attendees included Dr. Khaled Abdel Ghaffar, Deputy Prime Minister for Human Development and Minister of Health and Population; Dr. Mohamed Awad Tag El-Din, Presidential Advisor for Health and Prevention Affairs; Dr. Ali El-Ghamrawy, Chairperson of the Egyptian Drug Authority (EDA); and Dr. Hisham Stait, Chairman of the Unified Procurement Authority (UPA). Their participation highlights the strategic importance of this partnership in strengthening national health infrastructure and regional pharmaceutical capabilities.
This partnership represents a significant step toward sustainable healthcare solutions, local pharmaceutical innovation, and regional export growth, marking a new chapter in Egypt’s efforts to advance women’s health and family planning access across the continent.
